Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

Among parasitic diseases, morbidity and mortality caused by leishmaniasis are surpassed
only by malaria and lymphatic filariasis. However, estimation of the leishmaniasis disease …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

Cutaneous and mucosal leishmaniasis, caused in South America by Leishmania
braziliensis, is difficult to cure by chemotherapy (primarily pentavalent antimonials [SbV]) …

BACKGROUND: Cutaneous leishmaniasis (CL) has traditionally been underrecognized and
underreported. Improved awareness is warranted as the number of cases has increased as …

Miltefosine has been used in the treatment of several new world cutaneous leishmaniasis
(CL) species with variable efficacy. Our study is the first evidence on its clinical efficacy in …

Treatment options for cutaneous leishmaniasis in the United States are problematic because
the available products are either investigational, toxic, and/or of questionable effectiveness …

Introduction Leishmaniasis is an important public health problem in the Americas. A
Cochrane review published in 2009 analyzed 38 randomized controlled trials (RCT). We …